Patent US5610148A successfully refreshed from Google Patents.
US5610148A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Macroscopically oriented cell adhesion protein for wound treatment
Assignee: Intercytex Ltd
•
Filing: 1995-04-04
•
Granted: 1997-03-11
•
Expires: 2015-04-04
Abstract
Abstract A porous macroscopically undirectionally oriented cell adhesion protein may be used to promote and direct wound healing.
Inventors
- 👤 Robert Brown
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:33
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/78; A; A61; A61L; A61L15/00; A61L15/16; A61L15/22; A61L15/32; A61L27/00; A61L27/50; A61L27/54; A61K; A61K38/00; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/412
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
48 words
A method of treating a wound comprising applying an effective, non-toxic amount of a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein to the wound, in which fibrils of the cell adhesion protein are macroscopically unidirectionally oriented.
Claim 2
Independent Claim
48 words
A method of treating a wound comprising applying an effective, non-toxic amount of a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein to the wound, in which fibrils of the cell adhesion protein are macroscopically unidirectionally oriented.
Claim 3
Dependent Claim
39 words
A method according to claim 1 for treating a wound so as to promote wound healing, to direct wound healing, to improve the strength of the wound when healed or to improve the appearance of the wound when healed.
Claim 4
Dependent Claim
48 words
A process for producing a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein which process comprises forming and orienting cell adhesion protein fibrils from an aqueous solution thereof by applying continuous unidirectional motion and removing the solvent.
Claim 5
Dependent Claim
48 words
A process for producing a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein which process comprises forming and orienting cell adhesion protein fibrils from an aqueous solution thereof by applying continuous unidirectional motion and removing the solvent.
Claim 6
Dependent Claim
22 words
A process according to claim 3, wherein the concentration of the aqueous solution of cell adhesion protein is at least 0.7 mg/ml.
Claim 7
Dependent Claim
36 words
A wound dressing comprising a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein, in which fibrils of the cell adhesion protein are macroscopically unidirectionally oriented.
Claim 8
Dependent Claim
36 words
A wound dressing comprising a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein, in which fibrils of the cell adhesion protein are macroscopically unidirectionally oriented.
Claim 9
Dependent Claim
46 words
A wound dressing comprising a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein, in which fibrils of the cell adhesion protein are macroscopically unidirectionally oriented, which wound dressing has two or more non-parallel orientation directions.
Claim 10
Dependent Claim
46 words
A wound dressing comprising a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein, in which fibrils of the cell adhesion protein are macroscopically unidirectionally oriented, which wound dressing has two or more non-parallel orientation directions.
Claim 11
Independent Claim
88 words
A method of treating a wound, comprising the steps of: a) applying a non-toxic amount of a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein in which fibrils of the cell adhesion protein are macroscopically unidirectionally oriented to the wound and b) allowing the wound to heal while in contact with said macroscopically unidirectionally oriented cell adhesion protein in order to promote wound healing, direct wound healing or improve the appearance or strength of a healed wound.
Claim 12
Independent Claim
88 words
A method of treating a wound, comprising the steps of: a) applying a non-toxic amount of a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein in which fibrils of the cell adhesion protein are macroscopically unidirectionally oriented to the wound and b) allowing the wound to heal while in contact with said macroscopically unidirectionally oriented cell adhesion protein in order to promote wound healing, direct wound healing or improve the appearance or strength of a healed wound.
Claim 13
Independent Claim
70 words
A method of treating a wound, comprising the steps of: a) applying a non-toxic amount of a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein in which fibrils of the cell adhesion protein are macroscopically unidirectionally oriented to the wound and b) allowing the growth of autograft material promoted or directed by said macroscopically unidirectionally oriented cell adhesion protein.
Claim 14
Independent Claim
70 words
A method of treating a wound, comprising the steps of: a) applying a non-toxic amount of a porous macroscopically unidirectionally oriented cell adhesion protein selected from the group consisting of fibronectin, vitronectin and von Willebrand protein in which fibrils of the cell adhesion protein are macroscopically unidirectionally oriented to the wound and b) allowing the growth of autograft material promoted or directed by said macroscopically unidirectionally oriented cell adhesion protein.
Claim 15
Dependent Claim
33 words
A porous, macroscopically unidirectionally oriented cell adhesion protein, which is selected from the group consisting of fibronectin, vitronectin and von Willebrand protein, in which fibrils of the cell adhesion are macroscopically unidirectionally oriented.
Claim 16
Dependent Claim
33 words
A porous, macroscopically unidirectionally oriented cell adhesion protein, which is selected from the group consisting of fibronectin, vitronectin and von Willebrand protein, in which fibrils of the cell adhesion are macroscopically unidirectionally oriented.
Claim 17
Dependent Claim
16 words
The porous macroscopically unidirectionally oriented cell adhesion protein of claim 9 further comprising a therapeutic agent.
Claim 18
Dependent Claim
21 words
The porous macroscopically unidirectionally oriented cell adhesion protein of claim 10 wherein the therapeutic agent is one which promotes wound healing.
Claim 19
Dependent Claim
23 words
The porous macroscopically unidirectionally oriented cell adhesion protein of claim 11 wherein the therapeutic agent which promotes wound healing is a growth factor.
Claim 20
Dependent Claim
9 words
A protein according to claim 9 which is fibronectin.
References Cited (Backward Citations)
US4925924A
Cited
US4703108A
Cited
US4970298A
Cited
US5013732A
Cited
US4885295A
Cited
EP0455263A2
Cited
EP0221977A1
Cited
US4983580A
Cited
US5043429A
Cited
US5043429B1
Cited
EP0314109A2
Cited
WO1989005342A1
Cited
WO1989010135A1
Cited
EP0340628A2
Cited
US5043288A
Cited
US4973466A
Cited
US5124155A
Cited
EP0434836A1
Cited
EP0362526A2
Cited
EP0406428A1
Cited
US4955892A
Cited
EP0376189A2
Cited
WO1990008833A1
Cited
EP0410006A1
Cited
EP0386906A1
Cited
EP0384362A2
Cited
WO1990011365A1
Cited
WO1990012033A1
Cited
WO1990012580A1
Cited
WO1990013306A2
Cited
WO1990013653A1
Cited
WO1990013647A1
Cited
WO1990013566A1
Cited
US5120828A
Cited
WO1990013644A2
Cited
EP0397635A1
Cited
EP0397633A2
Cited
WO1990014418A1
Cited
EP0399806A1
Cited
WO1990015620A1
Cited
EP0437622A1
Cited
EP0412951A1
Cited
WO1991001380A1
Cited
EP0416250A2
Cited
WO1991003559A1
Cited
WO1991003252A1
Cited
WO1991004058A2
Cited
WO1991005048A1
Cited
EP0428266A1
Cited
WO1991005566A1
Cited
WO1991006315A1
Cited
WO1991007974A1
Cited
WO1991009122A1
Cited
EP0433817A1
Cited
WO1991009614A1
Cited
WO1991009874A1
Cited
WO1991010683A1
Cited
WO1991011462A2
Cited
WO1991012026A1
Cited
WO1991013152A1
Cited
WO1991013085A1
Cited
WO1991013093A1
Cited
WO1991013625A1
Cited
EP0459577A2
Cited
EP0468181A2
Cited
EP0466505A2
Cited
EP0469985A1
Cited
EP0473564A1
Cited
EP0479071A2
Cited
EP0477833A1
Cited
EP0480189A1
Cited
EP0482649A2
Cited
US5104856A
Cited
EP0488258A2
Cited
EP0488583A2
Cited
EP0503301A2
Cited
EP0499544A2
Cited
EP0501233A1
Cited
EP0505749A2
Cited
EP0502496A2
Cited
EP0503646A1
Cited
EP0503583A1
Cited
EP0505868A2
Cited
EP0507187A1
Cited
EP0507604A2
Cited
EP0509517A2
Cited
EP0509120A1
Cited
EP0510483A1
Cited
EP0512301A1
Cited
EP0512916A2
Cited
EP0522606A2
Cited
EP0514721A1
Cited
EP0514970A1
Cited
EP0517182A1
Cited
EP0517174A2
Cited
EP0519901A2
Cited
EP0526756A1
Cited
EP0527056A1
Cited
EP0529858A1
Cited
EP0529659A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-03-10 | 2000-09-09 | 2001-03-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-03-10 | 2004-09-09 | 2005-03-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-03-10 | 2008-09-09 | 2009-03-11 | $7700.00 | Window Closed / Lapsed |